TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings
TG Therapeutics (TGTX) is back in focus after its Q2 2026 earnings update, which combined higher revenue and raised full year guidance with lower net income and earnings per share.
See our latest analysis for TG Therapeutics.
The raised 2026 guidance and focus on BRIUMVI come after a sharp short term pullback, with a 7 day share price return of down 6.7% and 30 day share price return of down 10.1%. TG Therapeutics still shows strong momentum over longer periods, with a year to date share price return of 70.4% and a 3 year total shareholder return of well over 4x.
If the BRIUMVI story has you looking closer at healthcare and AI, this is also a useful moment to widen your watchlist with 42 healthcare AI stocks
After a big three year run and a sharp pullback around the Q2 2026 numbers, TG Therapeutics now sits at an interesting crossroads. Has the recent move already priced in most of BRIUMVI, or is there still clear upside left on the table, as the valuation screens suggest?
Most Popular Narrative: 3.5% Undervalued
At a last close of $49.88 versus a narrative fair value of $51.71, TG Therapeutics screens as slightly undervalued on the most followed storyline, which focuses on BRIUMVI-led growth and margin assumptions.
The upcoming launch of subcutaneous BRIUMVI and expanded market access are set to drive substantial long-term revenue and sales growth.
Strong commercial execution, demographic trends, and a lean operational model create pathways for ongoing market penetration and margin improvement.
Want to see what sits behind that fair value for TG Therapeutics? The narrative focuses on rapid top line expansion, shifting margins and a lower future earnings multiple. It examines which of those levers has the greatest impact.
Result: Fair Value of $51.71 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, TG Therapeutics still faces meaningful risk from its heavy reliance on BRIUMVI, as well as from increasing competition and pricing pressure across multiple sclerosis treatments.
Find out about the key risks to this TG Therapeutics narrative.
Next Steps
With TG Therapeutics showing both clear potential around BRIUMVI and real questions on concentration and competition, it makes sense to move fast and check the underlying data for yourself. To weigh up both sides, start with the 5 key rewards and 1 important warning sign.
Looking for more investment ideas beyond TG Therapeutics?
If TG Therapeutics has sharpened your focus, do not stop here. Broaden your opportunity set with a few targeted screeners that surface stocks matching different priorities.
- Target potential bargain opportunities by filtering for companies that look mispriced on quality and fundamentals using the 51 high quality undervalued stocks.
- Build a watchlist around capital protection and stability by starting with the 79 resilient stocks with low risk scores.
- Hunt for under-the-radar prospects that the market may be overlooking by checking the screener containing 17 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com